Exsulin Corp. releases clinical trial results for investigational diabetes drug

MINNEAPOLIS Results of a mid-stage clinical trial of a drug designed to restore the ability of the pancreas to produce insulin have appeared online in the journal Diabetes/Metabolism Research and Reviews, the drug’s manufacturer has announced.

Exsulin Corp. said it planned to move forward immediately on Exsulin (INGAP peptide), designed for use in patients with Type 1 and Type 2 diabetes.

“Since the landmark discovery of insulin in 1921, only incremental progress has been made in insulin therapy, which remains difficult and hazardous – particularly for people with [Type 1 diabetes],” Exsulin Corp. founder and chairman G. Alexander Fleming said in a statement. “These study results are very encouraging that Exsulin therapy could restore normal insulin secretion, which would allow insulin-dependent [Type 1 diabetes] and [Type 2 diabetes] patients to achieve normal glucose control while decreasing or ending their dependence on insulin treatment.”

Login or Register to post a comment.